MX2017009459A - Célula t asesina universal. - Google Patents

Célula t asesina universal.

Info

Publication number
MX2017009459A
MX2017009459A MX2017009459A MX2017009459A MX2017009459A MX 2017009459 A MX2017009459 A MX 2017009459A MX 2017009459 A MX2017009459 A MX 2017009459A MX 2017009459 A MX2017009459 A MX 2017009459A MX 2017009459 A MX2017009459 A MX 2017009459A
Authority
MX
Mexico
Prior art keywords
cells
modified
universal
immunogenic
tcr
Prior art date
Application number
MX2017009459A
Other languages
English (en)
Other versions
MX390756B (es
Inventor
Gaudernack Gustav
Marit Inderberg Suso Else
Kvalheim Gunnar
Wälchli Sébastien
Original Assignee
Univ Oslo Hf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oslo Hf filed Critical Univ Oslo Hf
Publication of MX2017009459A publication Critical patent/MX2017009459A/es
Publication of MX390756B publication Critical patent/MX390756B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4225—Growth factors
    • A61K40/4229—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se relaciona con una célula asesina natural (NK) modificada y su uso en medicina personalizada. Las células NK modificadas de la presente invención son no inmunogénicas, lo que significa que son capaces de administrarse a cualquier sujeto receptor sin ser rechazadas por el sistema inmune del anfitrión (son "universales"). En una primera modalidad las células NK no inmunogénicas se modifican para expresar CD3 para permitir un Receptor de Célula T (TcR) a ser expresado. En una modalidad adicional las células NK no inmunogénicas se modifican además para expresar un TcR junto con el co-receptor CD3. La co-expresión de CD3 con un TcR específico resulta en las células NK modificadas que muestran una citotoxicidad específica a antígeno hacia las células objetivo. Las células NK universales pueden por lo tanto, ser dirigidas contra antígenos específicos, y pueden por lo tanto ser utilizadas en medicina personalizada, particularmente en el campo de la oncología.
MX2017009459A 2015-01-23 2016-01-22 Célula t asesina universal MX390756B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1501175.2A GB201501175D0 (en) 2015-01-23 2015-01-23 A universal T-cell for personalised medicine
PCT/EP2016/051344 WO2016116601A1 (en) 2015-01-23 2016-01-22 Universal killer t-cell

Publications (2)

Publication Number Publication Date
MX2017009459A true MX2017009459A (es) 2018-04-11
MX390756B MX390756B (es) 2025-03-04

Family

ID=52673865

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009459A MX390756B (es) 2015-01-23 2016-01-22 Célula t asesina universal

Country Status (17)

Country Link
US (2) US11155786B2 (es)
EP (3) EP4681735A3 (es)
JP (1) JP6899333B2 (es)
KR (1) KR102479118B1 (es)
CN (1) CN107250351A (es)
AU (2) AU2016208475B2 (es)
CA (1) CA2973924C (es)
DK (1) DK3247791T3 (es)
EA (1) EA201791381A1 (es)
ES (1) ES2922231T3 (es)
GB (1) GB201501175D0 (es)
IL (1) IL253464B (es)
MX (1) MX390756B (es)
PL (1) PL3247791T3 (es)
PT (1) PT3247791T (es)
SG (1) SG11201705693XA (es)
WO (1) WO2016116601A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
WO2017192440A1 (en) * 2016-05-02 2017-11-09 Cerus Corporation Compositions and methods for improved nk cell therapies
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US20190358263A1 (en) 2016-12-07 2019-11-28 Oslo Universitetssykehus Hf Compositions and Methods for Cell Therapy
US11752172B2 (en) 2017-01-04 2023-09-12 Nova Southeastern University Natural killer (NK) cells expressing an antigen-specific functional T cell receptor (TCR) complex, methods for production thereof, and methods for therapeutic use thereof
GB201803178D0 (en) 2018-02-27 2018-04-11 Univ Oslo Hf Specific binding molecules for htert
CN112912727A (zh) * 2018-08-31 2021-06-04 因维克蒂斯股份有限公司 评估car功能性的方法
WO2020191358A1 (en) * 2019-03-20 2020-09-24 Bluebird Bio, Inc. Adoptive cell therapy
JP6977969B2 (ja) * 2019-03-22 2021-12-08 株式会社ガイアバイオメディシン 免疫細胞提供システム
EP3750547A1 (en) * 2019-06-13 2020-12-16 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Modified nk-92 cells, and therapeutic and diagnostic uses thereof
WO2021021930A1 (en) 2019-07-29 2021-02-04 Massachusetts Institute Of Technology Synthetic hydrogels for organogenesis
CN111662871A (zh) * 2020-06-11 2020-09-15 福建医科大学孟超肝胆医院(福州市传染病医院) 一种核酸适体功能化nk细胞及其制备与应用
BR112023005318A2 (pt) 2020-09-24 2023-04-25 Medigene Immunotherapies Gmbh Receptores de célula t específicos de prame e uso dos mesmos
WO2022095902A1 (en) * 2020-11-03 2022-05-12 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
GB202017873D0 (en) 2020-11-12 2020-12-30 Olso Unversitetssykehus Hf Method of determining DLBCL prognosis
KR20220160479A (ko) * 2021-05-27 2022-12-06 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
EP4404956B1 (en) 2021-09-21 2026-04-01 Oslo Universitetssykehus HF Binding proteins for terminal deoxynucleotidyl transferase (tdt)
WO2023078287A1 (en) * 2021-11-03 2023-05-11 Hangzhou Qihan Biotechnology Co., Ltd. Systems and methods for enhanced immunotherapies
WO2024020537A2 (en) * 2022-07-22 2024-01-25 Board Of Regents, The University Of Texas System Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy
CN121358493A (zh) 2023-06-20 2026-01-16 泽卢纳免疫疗法公司 增强或修饰nk细胞的方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5124251A (en) 1990-01-31 1992-06-23 Becton, Dickinson And Company CD3 ζ co-associated complex on CD16- NK cells
EP1690927A1 (en) 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
IL127142A0 (en) 1998-11-19 1999-09-22 Yeda Res & Dev Immune cells having predefined biological specificity
AU2002351239A1 (en) 2001-12-04 2003-06-17 Dana-Farber Cancer Institute, Inc. Antibody to latent membrane proteins and uses thereof
PL2921500T3 (pl) * 2004-07-10 2024-02-05 The Institute For Cancer Research Genetycznie zmodyfikowane ludzkie linie komórkowe naturalni zabójcy
EP1809738B1 (en) * 2004-11-02 2014-03-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services Compositions and methods for treating hyperproliferative disorders
US8518697B2 (en) 2006-04-04 2013-08-27 Washington University Single chain trimers and uses therefor
CN101631138A (zh) 2008-07-18 2010-01-20 深圳富泰宏精密工业有限公司 个人信息代理系统及方法
WO2010088160A1 (en) * 2009-01-28 2010-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
WO2013126785A1 (en) * 2012-02-22 2013-08-29 Ingenium Biotherapy Corporation A system for immunotherapy targeting tumor propagation and progression
ES2871349T3 (es) 2012-09-04 2021-10-28 Inven2 As Expansión selectiva y controlada de células NK educadas
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
CN105378078B (zh) 2013-02-04 2019-03-01 罗杰威廉姆斯医疗中心 用于治疗胃肠道间质瘤(gist)的方法和组合物
JP6425301B2 (ja) 2014-05-29 2018-11-21 国立大学法人富山大学 Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法
CN106459916A (zh) 2014-06-18 2017-02-22 乔治-施派尔-豪斯化学疗法研究所 作为细胞治疗剂的car‑表达nk‑92细胞
US20170274014A1 (en) * 2014-07-21 2017-09-28 Jennifer Brogdon Combinations of low, immune enhancing, doses of mtor inhibitors and cars
GB201501175D0 (en) * 2015-01-23 2015-03-11 Univ Oslo Hf A universal T-cell for personalised medicine

Also Published As

Publication number Publication date
EP4681735A3 (en) 2026-03-25
EP3247791B1 (en) 2022-05-04
EA201791381A1 (ru) 2018-02-28
PL3247791T3 (pl) 2022-09-05
SG11201705693XA (en) 2017-08-30
NZ733855A (en) 2023-10-27
EP4095239A1 (en) 2022-11-30
CA2973924C (en) 2024-06-04
US20220127574A1 (en) 2022-04-28
BR112017015631A2 (pt) 2018-03-13
ES2922231T3 (es) 2022-09-12
US20180010097A1 (en) 2018-01-11
KR20170121178A (ko) 2017-11-01
US11155786B2 (en) 2021-10-26
MX390756B (es) 2025-03-04
WO2016116601A1 (en) 2016-07-28
GB201501175D0 (en) 2015-03-11
KR102479118B1 (ko) 2022-12-16
IL253464A0 (en) 2017-09-28
AU2022200126A1 (en) 2022-02-10
IL253464B (en) 2022-04-01
JP2018512047A (ja) 2018-05-10
PT3247791T (pt) 2022-07-20
CN107250351A (zh) 2017-10-13
CA2973924A1 (en) 2016-07-28
JP6899333B2 (ja) 2021-07-07
EP3247791A1 (en) 2017-11-29
EP4681735A2 (en) 2026-01-21
AU2016208475B2 (en) 2021-10-14
AU2016208475A1 (en) 2017-08-03
DK3247791T3 (da) 2022-07-11

Similar Documents

Publication Publication Date Title
MX390756B (es) Célula t asesina universal
CU20170045A7 (es) Anticuerpos agonistas de anti-gitr y composiciones de los mismos
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CO2018010538A2 (es) Anticuerpos específicos del receptor de poliovirus humano (rvp)
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
CL2018001611A1 (es) Adenovirus del grupo b que codifica un anticuerpo o fragmento anti-tcr-complejo
CO2019007868A2 (es) Anticuerpos agonistas anti-icos y sus usos
BR112016020287A2 (pt) células resistentes a vírus e usos das mesmas
BR112017008710A2 (pt) composições e métodos para estimular a eficácia de imunoterapia celular adotiva
BR112019018863A8 (pt) Tcrs de alta afinidade específicos para mage-a1 e usos dos mesmos
AR101997A1 (es) Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3, y usos de los mismos
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
MX2016013159A (es) Expresion transgenica regulada por farmaco.
MX2017014822A (es) Composiciones y métodos para la reprogramación del tcr con proteínas de fusión.
EA201891459A1 (ru) Новое поколение антигенспецифических tcr
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
CR20200471A (es) PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)
MX391015B (es) Composiciones de nanoparticulas y usos de las mismas
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
PH12018502278A1 (en) Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
CO2019013000A2 (es) Proteínas de anticuerpo injertadas con citocinas y métodos de uso para trastornos relacionados con el sistema inmunitario
AR113834A1 (es) Receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos
AR113220A1 (es) Anticuerpos agonistas anti-icos y sus usos
UY36344A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer